Gastric Cancer - Global Strategic Business Report

The global market for Gastric Cancer was valued at US$3.3 Billion in 2024 and is projected to reach US$8.4 Billion by 2030, growing at a CAGR of 16.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Gastric Cancer market.

Global Gastric Cancer Market - Key Trends & Drivers Summarized

Why Is Gastric Cancer Research Becoming More Critical for Global Health?

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, particularly in regions such as East Asia, Central and Eastern Europe, and parts of South America. The increasing recognition of its global health burden has spurred significant advancements in both early detection and treatment options. Gastric cancer is particularly challenging because it is often diagnosed at an advanced stage when treatment options are limited, and survival rates are low. This has led to a growing focus on early diagnostic tools and technologies, such as biomarker testing and advanced imaging techniques, to identify the disease at its earliest stages. Furthermore, there is an increasing emphasis on understanding the molecular mechanisms underlying gastric cancer development, which is crucial for identifying targeted therapies. In particular, research into the role of Helicobacter pylori infection, genetic mutations, and dietary factors has gained momentum, as these are identified as key risk factors for the disease. As a result, funding for gastric cancer research has risen, supported by both public and private health organizations, to advance treatment methods and improve patient outcomes. With the rise in global awareness of the disease and its complex nature, scientists are exploring new therapeutic approaches such as immunotherapy, precision medicine, and personalized cancer treatments, all of which are driving innovations in the fight against gastric cancer.

How Are Advances in Treatment Shaping the Gastric Cancer Landscape?

The treatment landscape for gastric cancer has evolved significantly over the past decade, with advancements in both surgical techniques and systemic therapies offering new hope for patients. In the past, surgery was the main treatment option for early-stage gastric cancer, but only a small percentage of patients were candidates for curative surgery at the time of diagnosis. However, with the advent of minimally invasive procedures, patients are now able to undergo less invasive surgeries, which reduce recovery times and improve post-operative outcomes. In addition to surgery, chemotherapy, radiation therapy, and targeted therapies have become essential components of the treatment regimen, particularly for advanced stages of gastric cancer. Targeted therapies, such as trastuzumab (Herceptin), have shown efficacy in treating HER2-positive gastric cancers, which make up a significant proportion of gastric cancer cases. More recently, immunotherapy has emerged as a promising treatment option, particularly for patients with advanced gastric cancer. Immune checkpoint inhibitors such as pembrolizumab (Keytruda) have demonstrated encouraging results, offering new avenues for patients who have exhausted other treatment options. Moreover, advancements in molecular profiling and genetic testing are allowing for more personalized treatment plans tailored to an individual’s specific tumor characteristics. As more therapies become available, there is an increased focus on combining these modalities for better outcomes, with clinical trials actively investigating the benefits of dual therapies, immunotherapy combined with chemotherapy, and other synergistic approaches to treating gastric cancer.

What Are the Key Factors Contributing to the Increasing Incidence of Gastric Cancer?

Several factors are contributing to the increasing global incidence of gastric cancer, with lifestyle and environmental influences playing a significant role in disease development. One of the major risk factors is infection withHelicobacter pylori, a bacterium that is known to cause chronic inflammation and increase the risk of gastric cancer.H. pylori infection is particularly prevalent in developing countries, but with better sanitation and medical treatments, its prevalence is decreasing in developed nations. However, other lifestyle-related factors, such as poor diet, smoking, and alcohol consumption, continue to be major contributors to the rising incidence of gastric cancer. Diets rich in salted, smoked, or pickled foods, which are common in many parts of the world, have been linked to an increased risk of gastric cancer. Additionally, obesity and lack of physical activity are emerging as significant risk factors, as they are known to increase inflammation and alter gut microbiota, both of which contribute to carcinogenesis. Genetic predisposition also plays a role, with certain inherited syndromes, such as hereditary diffuse gastric cancer (HDGC), putting individuals at higher risk. Additionally, age is a significant factor, with the risk of developing gastric cancer increasing significantly in individuals over 50. The rise in the incidence of gastric cancer can therefore be attributed to a combination of environmental, dietary, genetic, and lifestyle factors, along with the challenges of early detection and the ability to effectively treat the disease in its advanced stages.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Treatment Market?

The growth of the gastric cancer treatment market is driven by several key factors, including advancements in medical research, increasing healthcare investments, and rising public awareness. As the incidence of gastric cancer continues to rise, particularly in countries with aging populations or high rates ofHelicobacter pylori infection, the demand for effective treatments is accelerating. The expansion of healthcare access, especially in developing countries, is also contributing to a larger patient population seeking treatment. Early diagnosis remains a significant challenge, but the development of more advanced screening and diagnostic tools has led to earlier detection in some regions, making treatment more effective and improving survival rates. The increasing focus on personalized medicine and precision oncology is another major driver, as treatments are becoming more tailored to an individual’s genetic and molecular profile, leading to more effective and targeted therapies. The integration of biomarkers and molecular diagnostics is enabling physicians to identify which treatments are most likely to benefit patients based on their tumor’s specific characteristics. Additionally, the growing interest in immunotherapy and its application to gastric cancer is another key factor propelling market growth. Immunotherapies, which harness the body’s immune system to fight cancer cells, are showing promise in treating patients with advanced or metastatic gastric cancer, and their development is accelerating the growth of the market. Furthermore, the pharmaceutical industry’s increasing focus on developing novel therapies and combination treatment regimens, as well as the rising number of clinical trials dedicated to gastric cancer, is expected to contribute to continued advancements and better patient outcomes, further driving the gastric cancer treatment market.

Report Scope

The report analyzes the Gastric Cancer market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Disease Types); Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy & Surgery); Drug Class (PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Other Drug Classes); Administration Route (Oral, Injectable); Distribution Channel (Specialty & Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Adenocarcinoma segment, which is expected to reach US$2.4 Billion by 2030 with a CAGR of a 14.8%. The Lymphoma segment is also set to grow at 19.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $893.1 Million in 2024, and China, forecasted to grow at an impressive 21.9% CAGR to reach $1.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Gastric Cancer Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Gastric Cancer Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Gastric Cancer Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Amgen Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, BeiGene Ltd. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 48 companies featured in this Gastric Cancer market report include:

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Biohit Oyj
• Bristol-Myers Squibb Company
• Celltrion Healthcare Co., Ltd.
• Eli Lilly and Company
• Exalenz Bioscience Ltd.
• F. Hoffmann-La Roche Ltd.
• GeneMatrix Inc.
• GSK plc
• Imugene Limited
• Jiangsu Hengrui Medicine Co.
• Merck & Co., Inc.
• Novartis AG
• OBI Pharma, Inc.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

• Tariff-adjusted market forecasts by region and segment
• Analysis of cost and supply chain implications by sourcing and trade exposure
• Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

• Finalized tariff impacts and new trade agreement effects
• Updated projections reflecting global sourcing and cost shifts
• Expanded country-specific coverage across the industry